Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 25, 2020 10:58 ET | Source: Sol-Gel Technologies Ltd.

UPDATE -- Sol-Gel Technologies to Present at Upcoming 2020 Solebury Trout Virtual Investor Conference

NESS ZIONA, Israel, March 25, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing...
March 24, 2020 16:05 ET | Source: Sol-Gel Technologies Ltd.

Sol-Gel Technologies Reports Full Year 2019 Financial Results and Corporate Update

Top-line generic product revenue of $22.8 million in fiscal 2019New Drug Applications for Epsolay® and Twyneo® remain on track for the second quarter and second half 2020, respectively NESS ZIONA,...
March 19, 2020 17:45 ET | Source: Sol-Gel Technologies Ltd.

Sol-Gel Technologies to Report Full Year 2019 Financial Results and Corporate Update

NESS ZIONA, Israel, March 19, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing...
February 19, 2020 09:25 ET | Source: Sol-Gel Technologies Ltd.

Sol-Gel to Present at the Cowen 40th Annual Health Care Conference

NESS ZIONA, Israel, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies (NASDAQ: SLGL), (“Sol-Gel”), a clinical-stage dermatology company focused on identifying, developing and commercializing...
February 14, 2020 06:45 ET | Source: Sol-Gel Technologies Ltd.

Sol-Gel Announces Pricing of Public Offering of Ordinary Shares and Warrants to Purchase Ordinary Shares

NESS ZIONA, Israel, Feb. 14, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing...
February 13, 2020 16:05 ET | Source: Sol-Gel Technologies Ltd.

Sol-Gel Announces Positive Topline Results from Open-Label, Long-Term Safety Study of Epsolay® for Treatment up to 52 Weeks

Successful topline results, strengthens Epsolay’s long-term safety and tolerability profile in the treatment of papulopustular rosacea Results pave the way for NDA submission in the second quarter of...
February 05, 2020 07:05 ET | Source: Sol-Gel Technologies Ltd.

Sol-Gel Provides Product Pipeline Updates and Anticipated Milestones for 2020

NESS ZIONA, Israel, Feb. 05, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”) a clinical-stage dermatology company focused on identifying, developing...
January 21, 2020 16:05 ET | Source: Sol-Gel Technologies Ltd.

Sol-Gel Announces Presentation of Data for its Topical Product Candidates for Acne and Rosacea at the 16th Annual Maui Derm for Dermatologists 2020 Meeting

NESS ZIONA, Israel, Jan. 21, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”) today announced the presentation of results from the Company’s Phase 3...
January 08, 2020 07:00 ET | Source: Sol-Gel Technologies Ltd.

Sol-Gel Hosts Investor Call to Discuss Positive Results from Twyneo® Phase 3 Program in Acne Vulgaris

Conference call with Sol-Gel management and U.S. key opinion leader today at 8:00 a.m. Eastern time NESS ZIONA, Israel, Jan. 08, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL)...
January 02, 2020 07:30 ET | Source: Sol-Gel Technologies Ltd.

Sol-Gel Announces Initiation of SGT-210 Phase 1 Proof of Concept Study in Palmoplantar Keratoderma (PPK)

NESS ZIONA, Israel, Jan. 02, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) today announced the initiation of a Phase 1 proof of concept clinical study of SGT-210, its novel,...